News | Cath Lab | May 19, 2016

New Data Supports St. Jude Medical FFR and LAA Closure Technology

Pair of studies from EuroPCR 2016 examine effectiveness of St. Jude’s FFR PressureWire and Amplatzer devices

St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer

May 19, 2016 — St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016. The studies — which include a look at how St. Jude Medical fractional flow reserve (FFR) technology impacts patient outcomes in acute coronary syndrome (ACS), and a comparison of left atrial appendage occlusion (LAAO) therapy to standard medical treatment – were presented during hotline sessions.

The latest studies contribute to the growing body of evidence supporting two St. Jude Medical cardiovascular therapies: FFR guidance with St. Jude Medical PressureWire technology to optimize percutaneous coronary intervention (PCI) procedures in patients with narrowed or blocked coronary arteries, as well as left atrial appendage closure for patients at increased risk of stroke as a result of atrial fibrillation.

St. Jude’s LAAO therapy devices include the original Amplatzer Cardiac Plug (ACP) and now the Amplatzer Amulet.

The PRIME-FFR study aimed to quantify the value of FFR when deciding the most appropriate treatment for patients with ACS. In the medical community, ACS is an umbrella term for medical conditions where blood supply to the heart is suddenly blocked. According to the American Heart Association, the blockage can be sudden and clog the entire artery, or it can be a moving clot that causes temporary blockage and decreased blood supply. The condition is more commonly referred to as a heart attack and needs to be addressed by a physician immediately.

In assessing the value of FFR, the study’s investigators defined management strategies for patients based on angiography results before performing FFR, and then made a final treatment strategy decision after performing FFR. Results showed that management strategy reclassification after performing routine FFR was high and that FFR is safe to use in ACS patients, indicating a management strategy guided by FFR safely leads to changes in physician decision-making.

In the second study, researchers assessed the impact of a LAAO in patients with atrial fibrillation (AF) and intracerebral hemorrhage (ICH) versus patients who received standard medical therapy. The left atrial appendage is a small pouch that hangs from the left atrium, which is considered to be unproblematic for most people with a regular heart rhythm. However, patients with AF experience a chaotic, uncontrolled heart rhythm, which can increase the likelihood of clot formation in the LAA, potentially resulting in a stroke. Because AF leads to an increased risk of stroke, a physician may seal off the LAA with an LAAO, or prescribe oral anticoagulants (OAC) to potentially reducing that risk.

While OACs are proven to be effective in reducing the risk of stroke in patients with AF, this therapy carries the risk of ICH, or recurrent bleeding, which is the leading cause of stroke mortality. Because the risk of reoccurring ICH is increased among patients who have previously experienced an ICH, many of these patients are denied OAC.

The LAAO in AF and ICH study found that patients with AF and a prior ICH who were treated with a St. Jude Medical LAAO device had a lower risk of ischemic stroke, major bleeding and all-cause mortality compared to patients treated with standard care, suggesting that LAAO offers a major clinical benefit.

“Patients with atrial fibrillation and previous intracerebral hemorrhage have an increased risk of ischemic stroke or repeated hemorrhage,” said Jens Erik Nielsen-Kudsk, M.D., DMSc, an associate professor of cardiologic medicine at Aarhus University and the study’s lead author. “The data from the this latest clinical assessment further shows that having a device like the Amplatzer LAA occlusion device implanted in these patients’ hearts offers them additional opportunity for improved cardiac health.”

For more information: www.sjm.com


Related Content

News | Atrial Fibrillation

May 26, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of Americans ...

Home May 26, 2023
Home
News | Atrial Fibrillation

May 18, 2023 — Vektor Medical, pioneers of technology to accurately map arrhythmias using only 12-lead ECG data ...

Home May 18, 2023
Home
News | Atrial Fibrillation

May 17, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmiatreatment and part of Johnson & Johnson ...

Home May 17, 2023
Home
News | Atrial Fibrillation

May 8, 2023 — An innovative three-step ablation approach including ethanol infusion of the vein of Marshall improves ...

Home May 08, 2023
Home
News | Atrial Fibrillation

April 25, 2023 — A score based on four readily available clinical and imaging parameters identifies the heart failure ...

Home April 25, 2023
Home
News | Atrial Fibrillation

April 20, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home April 20, 2023
Home
News | Atrial Fibrillation

April 18, 2023 — Medtronic today announced the 12-month findings that supported the Affera Mapping and Ablation System ...

Home April 18, 2023
Home
News | Atrial Fibrillation

April 6, 2023 — Atrial fibrillation (AFib) not only causes shortness of breath and palpitations but puts patients at ...

Home April 06, 2023
Home
Feature | Atrial Fibrillation

According to our latest study on "Atrial Fibrillation Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by ...

Home April 04, 2023
Home
News | Atrial Fibrillation

March 30, 2023 —Vektor Medical has announced that use of its vMap arrhythmia mapping system during complex atrial ...

Home March 30, 2023
Home
Subscribe Now